[go: up one dir, main page]

NO20030381L - Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser - Google Patents

Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser

Info

Publication number
NO20030381L
NO20030381L NO20030381A NO20030381A NO20030381L NO 20030381 L NO20030381 L NO 20030381L NO 20030381 A NO20030381 A NO 20030381A NO 20030381 A NO20030381 A NO 20030381A NO 20030381 L NO20030381 L NO 20030381L
Authority
NO
Norway
Prior art keywords
compounds
bicyclopyrazoles
processes
active
preparation
Prior art date
Application number
NO20030381A
Other languages
English (en)
Other versions
NO20030381D0 (no
NO325530B1 (no
Inventor
Daniele Fancelli
Valeria Pittala
Mario Varasi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24549630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20030381(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20030381D0 publication Critical patent/NO20030381D0/no
Publication of NO20030381L publication Critical patent/NO20030381L/no
Publication of NO325530B1 publication Critical patent/NO325530B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Bisyklopyrazolforbindelser av formel (I). som definert heri, er nyttige for behandling av sykdommer forbundet med disregulerte proteinkinaser.
NO20030381A 2000-08-10 2003-01-24 Bisyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske preparater som inneholder slike forbindelser NO325530B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63591400A 2000-08-10 2000-08-10
PCT/EP2001/008639 WO2002012242A2 (en) 2000-08-10 2001-07-25 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Publications (3)

Publication Number Publication Date
NO20030381D0 NO20030381D0 (no) 2003-01-24
NO20030381L true NO20030381L (no) 2003-02-24
NO325530B1 NO325530B1 (no) 2008-06-09

Family

ID=24549630

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030381A NO325530B1 (no) 2000-08-10 2003-01-24 Bisyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske preparater som inneholder slike forbindelser

Country Status (29)

Country Link
US (3) US7541354B2 (no)
EP (1) EP1320531B1 (no)
JP (2) JP4555547B2 (no)
KR (1) KR100904157B1 (no)
CN (2) CN102060857A (no)
AR (1) AR034137A1 (no)
AT (1) ATE480539T1 (no)
AU (2) AU8765401A (no)
BR (1) BR0113176A (no)
CA (1) CA2416527C (no)
CY (1) CY1110914T1 (no)
CZ (1) CZ2003591A3 (no)
DE (1) DE60143041D1 (no)
DK (1) DK1320531T3 (no)
EA (1) EA006381B1 (no)
EE (1) EE05405B1 (no)
ES (1) ES2349762T3 (no)
HU (1) HU229824B1 (no)
IL (2) IL153997A0 (no)
MX (1) MXPA03001169A (no)
MY (1) MY148632A (no)
NO (1) NO325530B1 (no)
NZ (1) NZ524475A (no)
PE (1) PE20020274A1 (no)
PL (1) PL213199B1 (no)
PT (1) PT1320531E (no)
SK (1) SK1882003A3 (no)
WO (1) WO2002012242A2 (no)
ZA (1) ZA200301813B (no)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05405B1 (et) * 2000-08-10 2011-04-15 Pharmacia Italia S.P.A. Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
UA80820C2 (en) 2002-05-15 2007-11-12 Janssen Pharmaceutica Nv N-substituted tricyclic 3-aminopyrazoles as pdfg receptor inhibitors
ES2411655T3 (es) * 2002-05-17 2013-07-08 Pfizer Italia S.R.L. Derivados de aminoindazol activos como inhibidores de quinasas, procedimiento para su preparación y composiciones farmacéuticas que los comprenden
DE60320560T2 (de) * 2002-07-17 2008-12-11 Pfizer Italia S.R.L. Heterobicyclische pyrazolderivate als kinaseinhibitoren
MXPA05000946A (es) * 2002-07-25 2005-05-16 Pharmacia Italia Spa Derivados heterociclicos condensados de pirazol como inhibidores de cinasa.
MXPA05000945A (es) * 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
CA2493625A1 (en) * 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
JP2006519816A (ja) * 2003-03-11 2006-08-31 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ キナーゼ阻害剤として活性なビシクロピラゾール誘導体、それらの製造方法、及びそれらを含んでなる医薬組成物
US7482354B2 (en) 2003-05-22 2009-01-27 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US20050043346A1 (en) * 2003-08-08 2005-02-24 Pharmacia Italia S.P.A. Pyridylpyrrole derivatives active as kinase inhibitors
BRPI0413438A (pt) * 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
AU2004276341B2 (en) * 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
JPWO2005063241A1 (ja) * 2003-12-26 2007-07-19 小野薬品工業株式会社 ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤
TW200526204A (en) 2004-02-03 2005-08-16 Pharmacia Italia Spa 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
DE602005026037D1 (de) * 2004-10-27 2011-03-03 Janssen Pharmaceutica Nv Tetrahydro pyridinyl pyrazole cannabinoid modulatoren
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
SI1838718T1 (sl) * 2005-01-10 2011-08-31 Pfizer Pirolopirazoli, zmogljivi inhibitorji kinaze
FR2880891B1 (fr) * 2005-01-19 2007-02-23 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
WO2007009883A1 (en) * 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
JP5303271B2 (ja) 2005-07-19 2013-10-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として有用な１Ｈ−チエノ［２，３−ｃ］ピラゾール化合物
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007064914A2 (en) * 2005-12-01 2007-06-07 Elan Pharmaceuticals, Inc. 5-(arylsulfonyl)-pyrazolopiperidines
JP5222731B2 (ja) * 2005-12-12 2013-06-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピロロ−ピラゾール誘導体
JP5219150B2 (ja) * 2005-12-12 2013-06-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
MY151455A (en) * 2005-12-21 2014-05-30 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
US9012487B2 (en) * 2006-03-03 2015-04-21 Nerviano Medical Sciences S.R.L. Bicyclo-pyrazoles active as kinase inhibitors
WO2007099166A1 (en) * 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
WO2007106391A1 (en) * 2006-03-10 2007-09-20 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
JP2009541219A (ja) * 2006-06-12 2009-11-26 メルク エンド カムパニー インコーポレーテッド 高眼圧治療のための眼科組成物
WO2008017465A1 (en) * 2006-08-10 2008-02-14 F. Hoffmann-La Roche Ag Bicyclic lactam derivatives, their manufacture and use as pharmaceutical agents
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
EP2089394B1 (en) 2006-10-11 2011-06-29 Nerviano Medical Sciences S.r.l. Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8183255B2 (en) 2007-02-07 2012-05-22 Pfizer, Inc. N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors
JP5337717B2 (ja) 2007-02-27 2013-11-06 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性なイソキノリノピロロピリジノン
JP5404601B2 (ja) * 2007-04-12 2014-02-05 ファイザー・インク 新規な３−アミド−ピロロ［３，４−ｃ］ピラゾール−５（１Ｈ，４Ｈ，６Ｈ）カルバルデヒド誘導体
EP2003129B1 (en) 2007-06-11 2017-08-09 Nerviano Medical Sciences S.r.l. 1H-Pyrido[3,4-B]indol-1-one and 2,3,4,9-Tetrahydro-1H-Beta-Carbolin-1-one Derivatives
CN102105148B (zh) 2008-07-24 2013-04-10 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
EP2376089B1 (en) 2008-11-17 2018-03-14 The Regents of the University of Michigan Cancer vaccine compositions and methods of using the same
CN102256972A (zh) 2008-12-18 2011-11-23 霍夫曼-拉罗奇有限公司 噻唑基-苯并咪唑类
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
AU2010343102B2 (en) 2009-12-29 2016-03-24 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2012020227A1 (en) 2010-08-11 2012-02-16 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
KR101913441B1 (ko) 2010-12-17 2018-10-30 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서 치환된 피라졸로-퀴나졸린 유도체
CN102134243A (zh) * 2011-03-04 2011-07-27 中国医学科学院医药生物技术研究所 具有抗肿瘤活性的双环氨基吡唑类衍生物
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
KR20140027366A (ko) * 2011-05-04 2014-03-06 포르마 티엠, 엘엘씨. Nampt의 억제를 위한 신규 화합물 및 조성물
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014074725A1 (en) * 2012-11-07 2014-05-15 Ohio State Innovation Foundation Substituted gemcitabine aryl amide analogs
EP2948453B1 (en) 2013-01-22 2017-08-02 Novartis AG Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
EP3004109A1 (en) 2013-05-27 2016-04-13 Novartis AG Imidazopyrrolidinone derivatives and their use in the treatment of disease
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA028035B1 (ru) 2013-05-28 2017-09-29 Новартис Аг Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015075665A1 (en) 2013-11-21 2015-05-28 Novartis Ag Pyrrolopyrrolone derivatives and their use as bet inhibitors
US9814716B2 (en) 2014-05-23 2017-11-14 Mingsight Pharmaceuticals, Inc. Treatment of autoimmune disease
AU2015337607B2 (en) 2014-10-31 2020-04-09 Ube Corporation Substituted dihydropyrrolopyrazole compound
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9550779B2 (en) 2014-12-30 2017-01-24 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
CN104530045A (zh) * 2015-01-14 2015-04-22 中国药科大学 吡唑并[4,3-c]四氢吡啶类c-Met激酶抑制剂及其制备方法和用途
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
EP3302448B1 (en) 2015-06-04 2023-10-25 Aurigene Oncology Limited Substituted heterocyclyl derivatives as cdk inhibitors
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
CA2989519C (en) 2015-06-15 2023-09-26 Ube Industries, Ltd. Substituted dihydropyrrolopyrazole derivative
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10987359B2 (en) 2016-06-29 2021-04-27 Novira Therapeutics, Inc. Oxadiazepinone derivatives and methods of treating hepatitis B infections
AU2017290755B2 (en) 2016-06-29 2021-07-01 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis B infections
US10954233B2 (en) 2016-09-09 2021-03-23 Novartis Ag Compounds and compositions as inhibitors of endosomal toll-like receptors
AU2017349797B2 (en) 2016-10-24 2020-05-21 Astrazeneca Ab 6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
UA125043C2 (uk) 2017-01-30 2021-12-29 Астразенека Аб Модулятори рецептора естрогену
EP3630775B1 (en) 2017-05-31 2022-12-14 ChemoCentryx, Inc. 6-5 FUSED RINGS AS C5a INHIBITORS
MX391392B (es) 2017-05-31 2025-03-21 Chemocentryx Inc ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES C5a.
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
SG11202003283TA (en) 2017-10-11 2020-05-28 Hoffmann La Roche Bicyclic compounds for use as rip1 kinase inhibitors
AR115131A1 (es) * 2017-11-02 2020-12-02 Aicuris Gmbh & Co Kg Altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
ES2980175T3 (es) * 2017-12-22 2024-09-30 Chemocentryx Inc Compuestos anulares fusionados en 6,5 sustituidos con diarilo como inhibidores de C5aR
CN111788184B (zh) * 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
EP3752511A4 (en) 2018-01-10 2021-12-29 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN111954525B (zh) 2018-04-02 2023-12-26 凯莫森特里克斯股份有限公司 稠合双环C5aR拮抗剂的前药
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
CN110878042B (zh) * 2018-09-05 2021-06-01 新发药业有限公司 一种n-取代基哌啶-3-酮的制备方法
US12304913B2 (en) 2018-11-14 2025-05-20 Ube Industries, Ltd. Dihydropyrrolopyrazole derivative
EP3902542A4 (en) * 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3962486A4 (en) * 2019-04-30 2023-01-25 Valo Health, Inc. ESCAPEMENT OF USP36
EP3999519A4 (en) 2019-07-17 2023-08-16 Nucorion Pharmaceuticals, Inc. CYCLIC DEOXYRIBONUCLEOTIDE COMPOUNDS
ES3031581T3 (en) * 2019-08-05 2025-07-09 Dana Farber Cancer Inst Inc Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof
CA3166135A1 (en) * 2019-12-24 2021-07-01 Dana-Farber Cancer Institute, Inc. The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
MX2022013258A (es) 2020-04-24 2022-11-14 Astrazeneca Ab Formulaciones farmaceuticas.
WO2021214253A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
CN115073471B (zh) * 2021-03-11 2023-03-21 沈阳药科大学 吡唑并四氢吡咯类衍生物、其制备方法和在医药上的应用
CN113563346A (zh) * 2021-08-19 2021-10-29 守恒(厦门)医疗科技有限公司 吡咯[3,4-c]并吡唑二酰胺类衍生物及其在抗肿瘤药物中的应用
CN115057860B (zh) * 2022-05-20 2024-02-09 四川大学华西医院 一种erk抑制剂及其制药用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) * 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) * 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
JP2944048B2 (ja) * 1993-07-06 1999-08-30 フアイザー・インコーポレイテツド 二環式テトラヒドロピラゾロピリジン
US5508300A (en) * 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
PL319758A1 (en) * 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6008230A (en) * 1995-10-16 1999-12-28 Fujisawa Pharmaceutical Co., Ltd. Quinoline compounds as H+ -ATPases
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
PL341356A1 (en) * 1997-12-22 2001-04-09 Bayer Ag Raf kinase inhibition employing aryl- and heteroaryl-substituted heterocyclic ureas
EE05405B1 (et) * 2000-08-10 2011-04-15 Pharmacia Italia S.P.A. Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
UA81790C2 (uk) * 2002-12-19 2008-02-11 Фармация Италия С.П.А. Заміщені піролопіразольні похідні як інгібітори кінази
US7141568B2 (en) * 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP5219150B2 (ja) * 2005-12-12 2013-06-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体

Also Published As

Publication number Publication date
KR20030027008A (ko) 2003-04-03
CZ2003591A3 (cs) 2003-06-18
US20070191386A1 (en) 2007-08-16
PT1320531E (pt) 2010-10-27
AR034137A1 (es) 2004-02-04
US20030171357A1 (en) 2003-09-11
CA2416527A1 (en) 2002-02-14
JP2004505977A (ja) 2004-02-26
HU229824B1 (en) 2014-08-28
EA006381B1 (ru) 2005-12-29
PL360663A1 (en) 2004-09-20
CA2416527C (en) 2009-12-22
JP2010111677A (ja) 2010-05-20
PL213199B1 (pl) 2013-01-31
ES2349762T3 (es) 2011-01-11
EP1320531A2 (en) 2003-06-25
IL153997A (en) 2014-01-30
CY1110914T1 (el) 2014-02-12
AU2001287654B2 (en) 2006-12-14
EA200300248A1 (ru) 2003-08-28
US20090221632A1 (en) 2009-09-03
KR100904157B1 (ko) 2009-06-23
PE20020274A1 (es) 2002-03-31
US7541354B2 (en) 2009-06-02
EP1320531B1 (en) 2010-09-08
IL153997A0 (en) 2003-07-31
BR0113176A (pt) 2003-06-17
DK1320531T3 (da) 2011-01-03
WO2002012242A2 (en) 2002-02-14
AU8765401A (en) 2002-02-18
CN102060857A (zh) 2011-05-18
NZ524475A (en) 2004-11-26
SK1882003A3 (en) 2003-06-03
HUP0300741A3 (en) 2005-12-28
MXPA03001169A (es) 2003-06-30
ZA200301813B (en) 2004-06-22
ATE480539T1 (de) 2010-09-15
EE200300054A (et) 2004-12-15
NO20030381D0 (no) 2003-01-24
US8273765B2 (en) 2012-09-25
JP5185243B2 (ja) 2013-04-17
EE05405B1 (et) 2011-04-15
JP4555547B2 (ja) 2010-10-06
MY148632A (en) 2013-05-15
WO2002012242A3 (en) 2002-06-06
DE60143041D1 (de) 2010-10-21
CN1447810A (zh) 2003-10-08
US7531531B2 (en) 2009-05-12
HUP0300741A2 (hu) 2003-11-28
NO325530B1 (no) 2008-06-09

Similar Documents

Publication Publication Date Title
NO20030381L (no) Bicyklopyrazoler som er aktive som kinaseinhibitorer, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder slikeforbindelser
DK1636236T3 (da) Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
NO995006L (no) Nye forbindelser
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
NO20041086L (no) Aminoindazolderivatrer aktive som kinaseinhibitorer, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som inneholder dem
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
NO20054842L (no) Kjemiske forbindelser
NO20060113L (no) Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer
NO20081844L (no) Terapeutiske forbindelser
NO20051695L (no) Nye spirokondenserte kinazolinoner og deres anvendelse som fosfodiestereaseinbibitorer
NO20070570L (no) Forbindelser.
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
NO20055891L (no) Kinazolinderivater som aurorakinaseinhibitorer
MXPA04005809A (es) Inhibidores de proteinas quinasas.
NO20063768L (no) 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer
WO2002018363A3 (en) 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees